EP Studies Should Return To Basics, FDA Says; CRT Trial Endpoints Assessed
This article was originally published in The Gray Sheet
Executive Summary
CDRH Division of Cardiovascular Devices Director Bram Zuckerman is warning manufacturers of an over-reliance on surrogate endpoints that the agency has observed in electrophysiology device trials
You may also be interested in...
CRT Should Slow Heart Failure Progression, Not Merely Lift Symptoms – Panel
Peak VO2 level is an impractical endpoint to use in clinical trials of cardiac resynchronization therapy (CRT) devices, panelists agreed at a recent Heart Failure Society of America event in Washington, D.C
Circulatory Panel Warms To Cardiac Freezor Despite Missed Trial Targets
CryoCath Technologies' Freezor is approvable, with conditions, for cardiac cryoablation despite failing to meet pre-determined safety and efficacy endpoints, FDA's Circulatory System Devices Panel concluded in a 7-3 vote March 6 in Gaithersburg, Md
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”